Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE-TBM trial in tuberculous meningitis
PACTR202306908320967Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, isoniazid, linezolid, pyrazinamide and ethambutol in meningeal tuberculosis and Tuberculosis (TB) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Modified Rankin Scale at 48 weeks. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
rifampicinisoniazidlinezolidpyrazinamideethambutol
03
Conditions
meningeal tuberculosisTuberculosis (TB)
Beyond the preview
Go deeper on PACTR202306908320967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202306908320967.